ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CAPS Capstone Therapeutics Corporation (QB)

4.10
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Capstone Therapeutics Corporation (QB) USOTC:CAPS OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.10 4.10 4.90 0.00 12:55:49

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

25/09/2019 9:01pm

Edgar (US Regulatory)


UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 0000887151

 

Capstone Therapeutics Corp.

 

(Exact name of registrant as specified in its charter)

 

1275 West Washington Street, Suite 104 Tempe, Arizona 85281 602-286-5520

 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $.0005 per share)
Preferred Share Purchase Rights (issued April 18, 2017)

 

(Title of each class of securities covered by this Form)

 

None

 

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)
Rule 12g-4(a)(2)
Rule 12h-3(b)(1)(i)
Rule 12h-3(b)(1)(ii)
Rule 15d-6
Rule 15d-22(b)

 

Approximate number of holders of record as of the certification or notice date:
Common Stock, par value $.0005 per share - 108

 

Preferred Share Purchase Rights (issued April 18, 2017) - 108

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Capstone Therapeutics Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: September 25, 2019 By:  /s/ John M. Holliman, III   
    John M. Holliman, III  
    Executive Chairman  

 

Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

 

 

 

 

 

 

 

 

 

 

 

 

1 Year Capstone Therapeutics (QB) Chart

1 Year Capstone Therapeutics (QB) Chart

1 Month Capstone Therapeutics (QB) Chart

1 Month Capstone Therapeutics (QB) Chart

Your Recent History

Delayed Upgrade Clock